UroGen Pharma (URGN) Competitors $10.75 +0.15 (+1.42%) Closing price 04:00 PM EasternExtended Trading$10.76 +0.01 (+0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. BHVN, TARS, GMTX, AAPG, BLTE, NAMS, MTSR, ARQT, RXRX, and DNLIShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Biohaven (BHVN), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), Metsera (MTSR), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Biohaven Tarsus Pharmaceuticals Gemini Therapeutics Ascentage Pharma Group International Belite Bio NewAmsterdam Pharma Metsera Arcutis Biotherapeutics Recursion Pharmaceuticals Denali Therapeutics UroGen Pharma (NASDAQ:URGN) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Is URGN or BHVN more profitable? Biohaven has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Biohaven N/A -225.12%-158.89% Do analysts recommend URGN or BHVN? UroGen Pharma currently has a consensus target price of $38.20, suggesting a potential upside of 255.35%. Biohaven has a consensus target price of $62.77, suggesting a potential upside of 238.12%. Given UroGen Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe UroGen Pharma is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Biohaven 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Do institutionals and insiders believe in URGN or BHVN? 91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer URGN or BHVN? In the previous week, Biohaven had 4 more articles in the media than UroGen Pharma. MarketBeat recorded 10 mentions for Biohaven and 6 mentions for UroGen Pharma. UroGen Pharma's average media sentiment score of 1.22 beat Biohaven's score of 0.76 indicating that UroGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UroGen Pharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, URGN or BHVN? UroGen Pharma has higher revenue and earnings than Biohaven. UroGen Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$90.40M5.48-$102.24M-$3.23-3.33BiohavenN/AN/A-$408.17M-$9.39-1.98 Which has more risk & volatility, URGN or BHVN? UroGen Pharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Does the MarketBeat Community believe in URGN or BHVN? Biohaven received 33 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 74.30% of users gave UroGen Pharma an outperform vote while only 67.33% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes37374.30% Underperform Votes12925.70% BiohavenOutperform Votes40667.33% Underperform Votes19732.67% SummaryUroGen Pharma beats Biohaven on 10 of the 17 factors compared between the two stocks. Remove Ads Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$495.51M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-3.416.7921.7317.81Price / Sales5.48225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book-3.875.866.464.00Net Income-$102.24M$141.86M$3.20B$247.23M7 Day Performance11.28%8.98%6.54%7.26%1 Month Performance-2.89%-12.65%-8.55%-6.26%1 Year Performance-28.81%-11.99%10.33%-0.18% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma3.9177 of 5 stars$10.75+1.4%$38.20+255.3%-29.8%$495.51M$90.40M-3.41200BHVNBiohaven3.5018 of 5 stars$17.86-3.9%$62.77+251.4%-65.2%$1.82BN/A-1.91239TARSTarsus Pharmaceuticals2.9463 of 5 stars$47.49+1.0%$63.67+34.1%+34.7%$1.82B$182.95M-12.4650Positive NewsGMTXGemini TherapeuticsN/A$41.22-9.9%N/A+21.7%$1.79BN/A-41.2230Gap UpHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$20.40-2.6%N/AN/A$1.78B$980.65M0.00600Gap DownBLTEBelite Bio2.8674 of 5 stars$55.67-2.2%$96.67+73.6%+58.8%$1.77BN/A-50.1510Short Interest ↓NAMSNewAmsterdam Pharma2.2865 of 5 stars$15.86+0.3%$43.33+173.2%-16.6%$1.74B$45.56M-6.104Short Interest ↑Gap DownHigh Trading VolumeMTSRMetseraN/A$16.45-2.1%$47.00+185.7%N/A$1.73BN/A0.0081High Trading VolumeARQTArcutis Biotherapeutics3.0563 of 5 stars$14.30-2.9%$18.80+31.5%+26.9%$1.70B$196.54M-7.99150RXRXRecursion Pharmaceuticals2.1183 of 5 stars$4.20-0.9%$8.25+96.4%-34.5%$1.69B$58.49M-2.75400News CoverageHigh Trading VolumeDNLIDenali Therapeutics4.1325 of 5 stars$11.60-1.5%$37.20+220.7%-27.3%$1.68B$330.53M-4.20430Analyst Revision Remove Ads Related Companies and Tools Related Companies Biohaven Competitors Tarsus Pharmaceuticals Competitors Gemini Therapeutics Competitors Ascentage Pharma Group International Competitors Belite Bio Competitors NewAmsterdam Pharma Competitors Metsera Competitors Arcutis Biotherapeutics Competitors Recursion Pharmaceuticals Competitors Denali Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
